These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 19057198)
1. Advances in diagnosis and treatment of eosinophilia. Sheikh J; Weller PF Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198 [TBL] [Abstract][Full Text] [Related]
2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808 [TBL] [Abstract][Full Text] [Related]
3. Hypereosinophilic syndrome and proliferative diseases. Ionescu MA; Wang L; Janin A Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987 [TBL] [Abstract][Full Text] [Related]
4. Practical approach to the patient with hypereosinophilia. Roufosse F; Weller PF J Allergy Clin Immunol; 2010 Jul; 126(1):39-44. PubMed ID: 20538328 [TBL] [Abstract][Full Text] [Related]
5. Causes of hypereosinophilia in 100 consecutive patients. Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Helbig G; Kyrcz-Krzemień S Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698 [TBL] [Abstract][Full Text] [Related]
10. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Gotlib J; Cross NC; Gilliland DG Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488 [TBL] [Abstract][Full Text] [Related]
11. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Pardanani A; Tefferi A Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Klion AD Hematology Am Soc Hematol Educ Program; 2005; ():209-14. PubMed ID: 16304382 [TBL] [Abstract][Full Text] [Related]
14. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S; Gotlib J Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533 [TBL] [Abstract][Full Text] [Related]
15. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351 [TBL] [Abstract][Full Text] [Related]
16. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659 [TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Helbig G; Klion AD Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638 [TBL] [Abstract][Full Text] [Related]